Phase I Study of mPEG-R-Crisantaspase Given IV

Inclusion Criteria: * Patients with any relapsed or refractory hematological malignancy, for which standard curative or life prolonging treatment does not exist, or is no longer effective or tolerable. * For the following hematological malignancies, patients must have received at least: * Low grade NHL: * 3 prior lines of therapy and ALL, * aggressive NHL and other hematological malignancies: * 2 prior lines of therapy. * Ages 18 to 50 years and * ECOG performance status of 0, 1 or 2, * ability to understand and to sign a written informed consent and * have a life expectancy of greater than or equal to 90 days Exclusion Criteria: * Any active CNS disease, * previous greater than or equal to grade 3 allergic reaction to Erwinase, * patients who have experienced a greater than or equal to grade 3 allergic reaction to E. coli L-asparaginase and who have never received E. chrysanthemi L-asparaginase after the occurrence of this reaction, * WBC count greater than 20 Gica/L, any of the following laboratory abnormalities if not due to hematologic malignancy (calculated creatinine clearance less than 50 mL/min, * serum SGOT/AST or SGPT?ALT greater than 2.5 x upper limit of normal, * serum total bilirubin greater than 2.0 mg/dL, except in the case of hemolytic anemia. * Patients cannot have a history of greater than or equal to grade 2 pancreatitis, * any history of allogeneic transplant, * receiving steroid therapy with a dose greater than 20 mg/day, * known HIV positive serology, * active hepatitis B or C, * any serious active disease or comorbid medical condition or psychiatric illness that would prevent the subject from signing the informed consent. * Pregnant or lactating females or women of child bearing potential not willing to use an adequate method of birth control for the duration of the study are not eligible.